AbbVie Androgel ‘Sham’ Patent Fight Turned Away By Supreme Court

The Supreme Court has turned down AbbVie Inc.'s request to step into a fight with the Federal Trade Commission over whether the drugmaker violated antitrust law when it sued a rival to block generic competition.

The FTC sued AbbVie in 2014 for allegedly using “sham” patent infringement litigation to block Perrigo Inc. from producing a generic version of the testosterone drug AndroGel. A district court and the U.S. Court of Appeals for the Third Circuit both ruled in the FTC’s favor.

The drugmaker appealed to the Supreme Court, alleging the decision set “dangerous precedent” for patent rights and the ...